Core Viewpoint - Tongrentang Medical Investment Co., Ltd. is making a third attempt to submit its prospectus for an IPO on the Hong Kong Stock Exchange, with CICC as the sole sponsor, which could lead to the establishment of the fourth listed company under the Tongrentang Group [1][3] Group 1: Company Overview - Tongrentang Medical has become the largest non-public Chinese traditional medicine hospital group in terms of outpatient and inpatient visits, holding a market share of 1.7% [3] - The company reported revenues of 911 million yuan, 1.153 billion yuan, and 1.175 billion yuan for the years 2022, 2023, and 2024, respectively, with adjusted net profits of -9.23 million yuan, 47.87 million yuan, and 61.73 million yuan [3] - The acquisition of Sanxi Tang has significantly contributed to Tongrentang Medical's performance, with revenues from Sanxi Tang accounting for 21.9%, 31.2%, and 31.8% of total revenues in 2022, 2023, and 2024, respectively [3][4] Group 2: Financial Performance - Sanxi Tang contributed to Tongrentang Medical's gross profit, with figures of 64 million yuan, 96.9 million yuan, and 91.8 million yuan for the years 2022, 2023, and 2024, representing 44.8%, 44.6%, and 41.3% of the total gross profit [3] - The gross margin for Tongrentang Medical has been declining, with rates of 39.6%, 20.2%, and 17.9% for the years 2022, 2023, and 2024, respectively [7] Group 3: Strategic Acquisitions and Partnerships - In 2024, Sanxi Tang obtained exclusive sales rights for the Tongrentang brand's An Gong Niu Huang Wan series products to retailers in Zhejiang Province, which is expected to boost sales [6] - The sales revenue from An Gong Niu Huang Wan for 2024 is projected to be 73.149 million yuan, with Sanxi Tang's wholesale revenue from this product accounting for 31% of Tongrentang Medical's health products sales [6][7] Group 4: Shareholder Dynamics - Following multiple shareholding changes, as of March 2024, Tongrentang Medical holds a 75% stake in Sanxi Tang, with the original controlling shareholders also retaining a stake [4][5] - The original controlling shareholders, Zhu Zhibiao and Pan Songqin, became shareholders of Tongrentang Medical through capital increase in March 2024, holding a combined 3.87% stake [5]

Group 1 - The article provides an overview of the investment activities of Hong Kong-listed companies on August 11, 2025, including new stock activities, earnings announcements, shareholder meetings, and dividend distributions [1] Group 2 - New stock activities include companies such as ZhiNuo Pharmaceutical-B (currently in the IPO process) and Zhonghui Biotechnology-B (listing date) [1] - Earnings announcements are scheduled for companies like Baosheng International, Yuanyuan Group, and Kang Shifu Holdings among others [1] - Shareholder meetings will be held for companies including Huatai Textile, Shandong Gold, and Sichuan Chengyu Expressway [1] - Dividend distributions are noted for companies like Jianbei Miao Miao and Kangnait Optical, with specific ex-dividend and payment dates mentioned [1]

Core Points - The "Tongrentang Cup" vocational skills competition has commenced, highlighting the importance of traditional Chinese medicine craftsmanship [1] - The competition includes new categories for traditional Chinese medicine production, emphasizing the significance of these skills in modern times [3] - The increased difficulty of the competition challenges participants to demonstrate comprehensive skills across multiple traditional medicine production techniques [5] Group 1: Competition Overview - The event features 35 participants in traditional Chinese medicine production and 100 in medicine identification, with 35 and 18 advancing to practical preliminaries respectively [3] - The addition of traditional Chinese medicine production as a new category aims to enhance the development and transmission of traditional skills [3] Group 2: Participant Performance - Notable performances include Sun Xiaoguang from Yizhuang Factory, who excelled in the pill-making process, completing the initial step in just half an hour [7] - Zhang Ziwei from Daxing Factory demonstrated exceptional skill in slicing, producing uniform slices of Huangqi that met standards [9] - Du Zongru from Liujiayao Factory showcased her expertise in honey pill production, effectively controlling the heat during the critical refining stage [12] Group 3: Advancement in Competition - A total of 13 participants from the traditional medicine production category and 10 from the medicine identification category advanced to the semifinals [14]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京同仁堂科技發展股份有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 652,080,000 RMB | | 1 | RMB | | 652,080,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 652,080,000 RMB | | 1 | RMB | | 652,080,000 | | 2. 股份分類 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部份內容而產生或因依賴該等內 容而引致之任何損失承擔任何責任。 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：1666） 股東特別大會通告 茲通告北京同仁堂科技發展股份有限公司（「本公司」）謹訂於二零二五年八月十八 日（星期一）下午一時三十分假座中華人民共和國（「中國」）北京市豐台區南三環中路20 號舉行股東特別大會（「股東特別大會」），藉以考慮及酌情通過下列決議案： – 1 – 1. 批准張春友先生為本公司第九屆董事會之執行董事及董事會建議的其薪酬； 並授權董事會與其訂立董事服務合約。 2. 批准溫凱婷女士為本公司第九屆董事會之執行董事及董事會建議的其薪酬； 並授權董事會與其訂立董事服務合約。 3. 批准董事會建議的本公司執行董事張毅先生之薪酬。 4. 批准董事會建議的本公司職工董事之薪酬。 5. 批准修訂本公司之股東會議事規則。 6. 批准修訂本公司之董事會議事規則。 特別決議案 7. 批准修訂本公司之公司章程（ ...

此乃要件 請即處理 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不會就因本通函全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承 擔任何責任。 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其他註冊證券交易商、銀行經 理、律師、專業會計師或其他專業顧問。 閣下如已將名下之北京同仁堂科技發展股份有限公司股份全部售出或轉讓，應立即將本通函及隨附之代理人委 任表格送交買主或承讓人或經手賣或轉讓之銀行、持牌證券交易商或其他代理商，以便轉交買主或承讓人。 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 （股份代號：1666） 建議委任董事及釐定董事之薪酬； 董事會函件載於本通函第3頁至第9頁。本公司謹訂於二零二五年八月十八日（星期一）下午一時三十分假座中國 北京市豐台區南三環中路20號舉行股東特別大會，大會通告載於本通函第127頁至第129頁。 （包括取消監事會及監事及設立職工董事）； 建議修訂股東會議事規則； 如 閣下擬委任代理人出席股東特別大會，務請儘快且無論如何須於股東特別大 ...

Group 1 - The core viewpoint of the article highlights the successful implementation of an intelligent financial system by Tongrentang Technology Company, which integrates cost data and enhances risk management and fund control capabilities [1][3] - The company received the "Demonstration Unit of Financial Digital Transformation for Chinese Enterprises" award at the 19th China CFO Forum, showcasing its innovative attempts in financial capability transformation [3] - The intelligent financial project addresses challenges such as fragmented business operations and inefficient fund management, which previously hindered decision-making speed and resource allocation [3][4] Group 2 - The digital platform integrates various data including funds, taxes, budgets, and costs, enabling consolidated management and intelligent accounting across the entire system [4] - The system allows for precise cost tracking of production batches, reducing the time required for cost accounting from 4 hours to just 15 minutes, and features a cost visualization function for detailed cost breakdowns [4] - The financial system provides real-time monitoring of fund inflows and outflows, enhancing decision-making confidence during operational meetings [4][5] Group 3 - The unified accounting standards and real-time fund monitoring enable the headquarters to exercise strong control over the entire system, transforming financial data into a strategic resource for high-quality development [5] - The company has deployed nearly a hundred analytical models based on the system platform, covering various business units such as budget analysis, production-sales coordination, profit insights, and efficiency evaluation [5]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全 部或任何部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 北京同仁堂科技發展股份有限公司（「本公司」）董事（「董事」）會（「董事會」） 謹此宣佈，於二零二五年七月十七日舉行之董事會會議已通過相關決議案，建 議對本公司之公司章程（「公司章程」）進行修訂（包括取消本公司監事會 （「監事會」）及監事（「監事」）及設立職工代表董事）。建議修訂公司章程 須待股東於本公司股東特別大會（「股東特別大會」）以特別決議案的方式批准後 生效。 为了與修訂後的公司章程相匹配并进行其他常规性修改，董事會亦決議建議對本 公司股東會議事規則（「股東會議事規則」）及董事會議事規則（「董事會議事 規則」）作出若干修訂。建議修訂股東會議事規則及董事會議事規則須待股東 於股東特別大會分別以普通決議案的方式批准後生效。 有關決議案將提交股東特別大會以供本公司股東（「股東」）考慮及批准。載 有上述有關決議案詳情之通函將適時寄發予股東。 （股份代號：1666） (1) 建議修訂公司章程（包括取消監事會 ...

Core Insights - The demand for summer heat-relief products has surged since July, with companies like Beijing Tongrentang Technology Development Co., Ltd. ramping up production of traditional remedies such as Ren Dan and Huo Xiang Zheng Qi Shui to meet market needs [1][3] Group 1: Product Development and Production - The company has adjusted its production capacity and efficiency to ensure timely supply of summer health products, including increasing staffing for summer medication production [1] - Modern and intelligent equipment has been integrated into the production process, such as the introduction of centrifugal coating granulators for standardized management of production processes [3] - Six types of summer health products, including Ren Dan and Huo Xiang Zheng Qi Shui, have been fully distributed to pharmacies nationwide, ensuring consumer safety and health during the summer [3] Group 2: Product Features and Benefits - Ren Dan is designed to alleviate discomfort caused by high temperatures, utilizing ingredients like menthol and borneol to provide a cooling effect [7] - Huo Xiang Zheng Qi Shui addresses issues related to heat and humidity, using a classic formula that includes Huo Xiang as the main ingredient to relieve symptoms like headaches and gastrointestinal discomfort [5] - Sheng Mai Yin serves as an energy supplement for those who sweat excessively in summer, featuring ingredients like red ginseng and wheat to nourish and hydrate [9]

Core Viewpoint - Tong Ren Tang is expanding its business by adding a new publicly listed company, Beijing Tong Ren Tang Medical and Elderly Investment Co., Ltd., which focuses on medical and elderly care services [2][12]. Group 1: Company Overview - Tong Ren Tang currently has three listed companies: Tong Ren Tang Co., Ltd. (600085.SH) with a market value of 48.7 billion RMB, Tong Ren Tang Technology (01666.HK) with a market value of 6.3 billion HKD, and Tong Ren Tang Guoyao (03613.HK) with a market value of 7.6 billion HKD [2]. - The new company, Tong Ren Tang Medical and Elderly, was established in 2015 and has been acquiring stakes in various medical institutions since 2019 [3][5]. Group 2: Business Development - Tong Ren Tang Medical and Elderly has grown to become the second-largest player in the non-public Chinese medicine hospital service industry within seven years, establishing a network of 12 owned medical institutions and one internet hospital [5]. - The company has adopted an acquisition strategy, acquiring control of several healthcare facilities and expanding its presence in the Yangtze River Delta region [3][5]. Group 3: Financial Performance - In 2024, Tong Ren Tang Medical and Elderly reported total revenue of 1.175 billion RMB, with a gross profit margin of 18.93% and a net profit attributable to shareholders of 36.86 million RMB [9]. - The majority of revenue comes from medical services, which accounted for 84.05% of total revenue, generating a gross profit of 162 million RMB [6][9]. Group 4: Future Plans - The company is preparing to open new hospitals, including Qiqihar Tong Ren Tang Traditional Chinese Medicine Hospital and Shunyi Tong Ren Tang Traditional Chinese Medicine Hospital, expected to open by the end of 2025 [10][11]. - Plans for an IPO on the Hong Kong stock market are underway to raise funds for expanding its medical service network and improving operational capabilities [12].